scholarly article | Q13442814 |
P50 | author | Leonardo Mottola | Q59694970 |
Rosanna Santoro | Q59694971 | ||
Alessandra Mangia | Q60050616 | ||
P2093 | author name string | Alessandra Mangia | |
Leonardo Mottola | |||
Rosanna Santoro | |||
P2860 | cites work | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 |
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus | Q24596652 | ||
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
Host Genetic Factors and Antiviral Immune Responses to Hepatitis C Virus | Q27487445 | ||
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. | Q34177249 | ||
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. | Q36967081 | ||
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis | Q42913315 | ||
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin | Q42980402 | ||
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 | ||
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response | Q42998430 | ||
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients | Q43001830 | ||
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. | Q43031828 | ||
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients | Q43033484 | ||
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. | Q43034706 | ||
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection | Q43034871 | ||
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. | Q43035545 | ||
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus | Q43037069 | ||
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response | Q43041800 | ||
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring | Q44780715 | ||
P433 | issue | 47 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatitis C | Q154869 |
Hepatitis C virus | Q708693 | ||
P304 | page(s) | 8924-8928 | |
P577 | publication date | 2013-12-01 | |
P1433 | published in | World Journal of Gastroenterology | Q15708885 |
P1476 | title | Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients | |
P478 | volume | 19 |
Q35824222 | 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial |
Q38266253 | Cytokines and HCV-related autoimmune disorders |
Q40642039 | Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. |
Q36402309 | Genetic predictors of the response to the treatment of hepatitis C virus infection |
Q37437190 | HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. |
Q36070215 | Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. |
Q35226081 | Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study |
Q34506224 | Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. |
Q41493589 | The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection |
Q50283919 | Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3. |
Search more.